Email updates

Keep up to date with the latest news and content from BMC Public Health and BioMed Central.

Open Access Research article

Do advertisements for antihypertensive drugs in Australia promote quality prescribing? A cross-sectional study

Brett D Montgomery1*, Peter R Mansfield23, Geoffrey K Spurling4 and Alison M Ward5

Author Affiliations

1 Discipline of General Practice, School of Primary, Aboriginal and Rural Health Care, University of Western Australia, Claremont, Western Australia, Australia

2 Discipline of General Practice, University of Adelaide, Adelaide, South Australia, Australia

3 Healthy Skepticism, Willunga, South Australia, Australia

4 Discipline of General Practice, University of Queensland, Herston, Queensland, Australia

5 Department of Primary Health Care, University of Oxford, Headington, Oxford, UK

For all author emails, please log on.

BMC Public Health 2008, 8:167  doi:10.1186/1471-2458-8-167

Published: 20 May 2008



Antihypertensive medications are widely prescribed by doctors and heavily promoted by the pharmaceutical industry. Despite strong evidence of the effectiveness and cost-effectiveness of thiazide diuretics, trends in both promotion and prescription of antihypertensive drugs favour newer, less cost-effective agents. Observational evidence shows correlations between exposure to pharmaceutical promotion and less ideal prescribing. Our study therefore aimed to determine whether print advertisements for antihypertensive medications promote quality prescribing in hypertension.


We performed a cross-sectional study of 113 advertisements for antihypertensive drugs from 4 general practice-oriented Australian medical publications in 2004. Advertisements were evaluated using a quality checklist based on a review of hypertension management guidelines. Main outcome measures included: frequency with which antihypertensive classes were advertised, promotion of thiazide class drugs as first line agents, use of statistical claims in advertisements, mention of harms and prices in the advertisements, promotion of assessment and treatment of cardiovascular risk, promotion of lifestyle modification, and targeting of particular patient subgroups.


Thiazides were the most frequently advertised drug class (48.7% of advertisements), but were largely promoted in combination preparations. The only thiazide advertised as a single agent was the most expensive, indapamide. No advertisement specifically promoted any thiazide as a better first-line drug. Statistics in the advertisements tended to be expressed in relative rather than absolute terms. Drug costs were often reported, but without cost comparisons between drugs. Adverse effects were usually reported but largely confined to the advertisements' small print. Other than mentioning drug interactions with alcohol and salt, no advertisements promoted lifestyle modification. Few advertisements (2.7%) promoted the assessment of cardiovascular risk.


Print advertisements for antihypertensive medications in Australia provide some, but not all, of the key messages required for guideline-concordant care. These results have implications for the regulation of drug advertising and the continuing education of doctors.